Home › Research › Drug development
Clinical Benefits and Risks of Antiamyloid Antibodies in Sporadic Alzheimer Disease: Systematic Review and Network Meta-Analysis With a Web Application
Jeremic D, Navarro-Lopez JD, Jimenez-Diaz L.. Journal of medical Internet research, 2025-04-07
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Background Despite the increasing approval of antiamyloid antibodies for Alzheimer disease (AD), their clinical relevance and risk-benefit profile remain uncertain. The heterogeneity of AD and the limited availability of long-term clinical data make it difficult to establish a clear rationale for selecting one treatment over another. Objective The aim of this work was to assess and compare the efficacy and safety of antiamyloid antibodies through an interactive online meta-analytic approach by performing conventional pair-wise meta-analyses and frequentist and Bayesian network meta-analyses of phase II and III clinical trial results.
What this study adds
Evidence grade: High
This is a pooled review of 21,236 participants. This meta-analysis of phase II and III trials assessed the efficacy and safety of antiamyloid antibodies, but notes that limited long-term clinical data make it hard to establish a clear rationale for choosing one treatment over another. It does not report a definitive clinical benefit.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Jeremic, D., Navarro-Lopez, J. D., & Jimenez-Diaz, L. (2025). Clinical Benefits and Risks of Antiamyloid Antibodies in Sporadic Alzheimer Disease: Systematic Review and Network Meta-Analysis With a Web Application. Journal of medical Internet research. https://doi.org/10.2196/68454
Vancouver
Jeremic D, Navarro-Lopez JD, Jimenez-Diaz L. Clinical Benefits and Risks of Antiamyloid Antibodies in Sporadic Alzheimer Disease: Systematic Review and Network Meta-Analysis With a Web Application. Journal of medical Internet research. 2025. doi:10.2196/68454. PMID: 40194268.
BibTeX
@article{jeremic2025-40194268,
author = {Jeremic, D. and Navarro-Lopez, J. D. and Jimenez-Diaz, L.},
title = {{Clinical Benefits and Risks of Antiamyloid Antibodies in Sporadic Alzheimer Disease: Systematic Review and Network Meta-Analysis With a Web Application}},
journal = {Journal of medical Internet research},
year = {2025},
doi = {10.2196/68454},
pmid = {40194268},
url = {https://doi.org/10.2196/68454}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- The heterogeneity of AD and the limited availability of long-term clinical data make it difficult to establish a clear rationale for selecting one treatment over another.
- Objective The aim of this work was to assess and compare the efficacy and safety of antiamyloid antibodies through an interactive online meta-analytic approach by performing conventional pair-wise meta-analyses and frequentist and Bayesian network meta-analyses of phase II and III clinical trial results.
- To achieve this, we developed AlzMeta.app 2.0, a freely accessible web application that enables researchers and clinicians to evaluate the relative and absolute risks and benefits of these therapies in real time, incorporating different prior choices and assumptions of baseline risks of disease progression and adverse events.
- Methods We adhered to PRISMA-NMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for reporting of systematic reviews with network meta-analysis) and GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) guidelines for reporting and rating the certainty of evidence.
Why it matters
This meta-analysis of phase II and III trials assessed the efficacy and safety of antiamyloid antibodies, but notes that limited long-term clinical data make it hard to establish a clear rationale for choosing one treatment over another. It does not report a definitive clinical benefit.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Study designmeta-analysis
- Participants21,236
- Evidence strengthHigh
How this study scored 62/100
Published in a peer-reviewed journal, and it is a meta-analysis pooling many studies. Scored zero for effect reported because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of medical Internet research) |
| Journal's citation record | 3 / 4 | Journal of Medical Internet Research: journal h-index 286 (OpenAlex, 2026-10-29) |
| Study design | 12 / 12 | A meta-analysis pooling many studies |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 4 / 4 | 21,236 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | A review of other studies — randomization is not credited here |
| Times cited | 2 / 7 | Cited 13 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 4.3 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 2 / 6 | Cited 2.5× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 2 other studies in this library |
| Still being cited | 1 / 4 | Cited 13 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Lydia Jiménez‐Díaz: h-index 22 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | University of Castilla-La Mancha: institution h-index 351 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40194268) |
| Free to read | 2 / 2 | Free to read |
| Total | 62 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.2196/68454
- PubMed: 40194268
- Original source →
- Free full text: Journal of Medical Internet Research →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 17.
Later studies that cite this one
2 studies in the alzhub library list this one in their references.
Related studies in Drug development from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.